Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
3,085 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03722420 | Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China) | active not recruiting | Phase 3 | 238 | Il-Yang Pharm. Co., Ltd.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04035486 | A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)(FLAURA2) | active not recruiting | Phase 3 | 587 | AstraZenecaINDUSTRY | 21 |
| Sep 3, 2026 |
| clinicaltrials |
| NCT04873362 | A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy(Astefania) | active not recruiting | Phase 3 | 1,188 | Hoffmann-La RocheINDUSTRY | 32 | Sep 3, 2026 | clinicaltrials |
| NCT05568095 | A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body(STAR-221) | completed | Phase 3 | 1,040 | Arcus Biosciences, Inc.INDUSTRY | 29 | Sep 3, 2026 | clinicaltrials |
| NCT05840341 | Clinical Efficacy of QYHJ and Standard Chemotherapy in the Treatment of Advanced Pancreatic Cancer | completed | Phase 3 | 305 | Fudan UniversityOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06084936 | A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma(GLOBRYTE) | recruiting | Phase 3 | 182 | Hoffmann-La RocheINDUSTRY | 13 | Sep 3, 2026 | clinicaltrials |
| NCT06129864 | A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy(eVOLVE-HNSCC) | recruiting | Phase 3 | 1,145 | AstraZenecaINDUSTRY | 23 | Sep 3, 2026 | clinicaltrials |
| NCT06136624 | Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)(OMAHA-003) | recruiting | Phase 3 | 1,310 | Merck Sharp & Dohme LLCINDUSTRY | 36 | Sep 3, 2026 | clinicaltrials |
| NCT06422143 | Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] | recruiting | Phase 3 | 851 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Sep 3, 2026 | clinicaltrials |
| NCT06837896 | Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer | completed | Phase 3 | 111 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06921785 | Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma(ARTEMIDE-HCC01) | recruiting | Phase 3 | 1,220 | AstraZenecaINDUSTRY | 20 | Sep 3, 2026 | clinicaltrials |
| NCT06989112 | DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer(DE-01) | recruiting | Phase 3 | 600 | AstraZenecaINDUSTRY | 23 | Sep 3, 2026 | clinicaltrials |
| NCT07413939 | RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive(BREnnA) | recruiting | Phase 2 / Phase 3 | 650 | Hoffmann-La RocheINDUSTRY | 25 | Sep 3, 2026 | clinicaltrials |
| NCT07509099 | Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC | not yet recruiting | Phase 3 | 316 | Ji DongmeiOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05405166 | SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM(IRAKLIA) | active not recruiting | Phase 3 | 531 | SanofiINDUSTRY | 21 | Sep 2, 2026 | clinicaltrials |
| NCT05862285 | A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study(UmbrellaMAX) | recruiting | Phase 3 | 100 | Hoffmann-La RocheINDUSTRY | 15 | Sep 2, 2026 | clinicaltrials |
| NCT05939180 | VA vs DA for Newly Diagnosed Hig-risk AML | recruiting | Phase 2 / Phase 3 | 116 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07083154 | Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study) | recruiting | Phase 3 | 420 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03998254 | Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023) | active not recruiting | Phase 3 | 6,000 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06712355 | Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer | recruiting | Phase 3 | 621 | BioNTech SEINDUSTRY | 14 | Sep 1, 2026 | clinicaltrials |
| NCT07381660 | SBRT Versus Surgical Resection for Small HCC | recruiting | Phase 3 | 390 | Sun Yat-sen UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07720193 | A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC | not yet recruiting | Phase 3 | 280 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07796789 | Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma | recruiting | Phase 3 | 204 | Sun Yat-sen UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07797153 | JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer | not yet recruiting | Phase 3 | 368 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07797218 | Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC | recruiting | Phase 3 | 220 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT04538664 | A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions(PAPILLON) | active not recruiting | Phase 3 | 308 | Janssen Research & Development, LLCINDUSTRY | 26 | Aug 31, 2026 | clinicaltrials |
| NCT06976190 | A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(Magic-C002) | recruiting | Phase 3 | 446 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT04170283 | A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib | active not recruiting | Phase 3 | 955 | BeOne MedicinesINDUSTRY | 18 | Aug 28, 2026 | clinicaltrials |
| NCT04971226 | A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP | active not recruiting | Phase 3 | 405 | Novartis PharmaceuticalsINDUSTRY | 29 | Aug 28, 2026 | clinicaltrials |
| NCT05171816 | Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort) | active not recruiting | Phase 3 | 110 | AstraZenecaINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05298423 | Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)(KEYVIBE-006) | completed | Phase 3 | 610 | Merck Sharp & Dohme LLCINDUSTRY | 25 | Aug 28, 2026 | clinicaltrials |
| NCT05303519 | SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)(SIGMA) | recruiting | Phase 3 | 365 | Nuvation Bio Inc.INDUSTRY | 3 | Aug 28, 2026 | clinicaltrials |
| NCT06132958 | Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)(TroFuse-005) | active not recruiting | Phase 3 | 710 | Merck Sharp & Dohme LLCINDUSTRY | 31 | Aug 28, 2026 | clinicaltrials |
| NCT06459180 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) | active not recruiting | Phase 3 | 686 | Merck Sharp & Dohme LLCINDUSTRY | 32 | Aug 28, 2026 | clinicaltrials |
| NCT07205822 | A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer(TB06) | recruiting | Phase 3 | 100 | AstraZenecaINDUSTRY | 6 | Aug 28, 2026 | clinicaltrials |
| NCT07235319 | PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC | recruiting | Phase 3 | 260 | Sun Yat-sen UniversityOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07791745 | A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With or Without Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. | not yet recruiting | Phase 2 / Phase 3 | 362 | Taizhou Mabtech Pharmaceutical Co.,LtdINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT04540211 | A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma(SKYSCRAPER-08) | completed | Phase 3 | 461 | Hoffmann-La RocheINDUSTRY | 5 | Aug 27, 2026 | clinicaltrials |
| NCT05338970 | HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy | active not recruiting | Phase 3 | 586 | Daiichi SankyoINDUSTRY | 21 | Aug 27, 2026 | clinicaltrials |
| NCT06158841 | Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma(CERVINO) | active not recruiting | Phase 3 | 421 | AbbVieINDUSTRY | 25 | Aug 27, 2026 | clinicaltrials |
| NCT07201337 | Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma. | active not recruiting | Phase 3 | 700 | Sun Yat-sen UniversityOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07730489 | A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan | not yet recruiting | Phase 3 | 130 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07789184 | Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy | not yet recruiting | Phase 3 | 170 | Hua Huang, MD, PhDOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07790380 | FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy. | not yet recruiting | Phase 3 | 480 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT03615326 | Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) | completed | Phase 3 | 738 | Merck Sharp & Dohme LLCINDUSTRY | 20 | Aug 26, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials